DAPA-ICU Trial
Cross-source consensus on DAPA-ICU Trial from 1 sources and 4 claims.
1 sources · 4 claims
Dosage & preparation
Other
Other
Highlighted claims
- DAPA-ICU is designed as a multicentre, double-blind, randomised, placebo-controlled trial of dapagliflozin after ICU discharge. — Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU)
- The trial plans to enrol 600 adults across 16 ICUs in France. — Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU)
- Participants are randomised equally to dapagliflozin 10 mg once daily or matching placebo for one year. — Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU)
- The study began on 1 October 2025 and is planned to end on 6 November 2028. — Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU)